RETRACTED: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer (Retracted Article)

被引:73
|
作者
Taylor, Douglas D. [1 ]
Gercel-Taylor, Cicek [1 ]
Parker, Lynn P. [1 ]
机构
[1] Univ Louisville, Sch Med, Div Gynecol Oncol, Dept Obstet Gynecol & Womens Hlth, Louisville, KY 40292 USA
关键词
Ovarian cancer; Early detection; Autoantibodies; CELL-LINES; P53; PROTEIN; HEPATOCELLULAR-CARCINOMA; IMMUNE-RESPONSE; HIGH-THROUGHPUT; BREAST-CANCER; AUTOANTIBODIES; ANTIGENS; IDENTIFICATION; BIOMARKERS;
D O I
10.1016/j.ygyno.2009.06.031
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Most ovarian cancers are diagnosed at advanced stage (67%) and prospects for significant improvement in survival reside in early diagnosis. Our objective was to validate our array assay for the identification of ovarian cancer based on quantitation of tumor-reactive IgG. Methods. The diagnostic array utilizes specific exosome-derived antigens to detect reactive IgG in patient's sera. Specific protein targets were isolated by immunoaffinity from exosomes derived from ovarian tumor cell lines. Sera were obtained from age-matched female volunteers, women with benign ovarian disease and with ovarian cancer. Immunoreactivity was also compared between exosomal proteins and their recombinant counterparts. Results. Sera from ovarian cancer patients exhibited significantly greater immunoreactivities than either normal controls or women with benign disease (both considered negative to all antigens tested). Reactivities with nucleophosmin, cathepsin D, p53, and SSX common antigen for patients with all stages of ovarian cancer were significantly higher than for controls and women with benign ovarian disease. Reactivity with placental type alkaline phosphatase, TAG 72, survivin, NY-ESO-1, GRP78, and Muc16 (CA125) allowed the differentiation between Stage III/IV and early stage ovarian cancer. Conclusions. The quantitation of circulating tumor-reactive IgG can be used to identify the presence of ovarian cancer. The analyses of IgG recognition of specific exosomal antigens allows for the differentiation of women with benign ovarian masses from ovarian cancer, as well as distinguishing early and late stage ovarian cancers. Thus, the quantitative assessment of IgG reactive with specific tumor-derived exosomal proteins can be used as diagnostic markers for ovarian cancer. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:112 / 120
页数:9
相关论文
共 50 条
  • [1] Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer
    Taylor, Douglas D.
    Gercel-Taylor, Cicek
    Parker, Lynn P.
    GYNECOLOGIC ONCOLOGY, 2023, 175 : 193 - 193
  • [2] RETRACTION: Patient-derived tumor reactive antibodies as diagnostic markers for ovarian cancer (Retraction of Vol 115, Pg 112, 2009)
    Taylor, Douglas D.
    Gercel-Taylor, Cicek
    Parker, Lynn P.
    GYNECOLOGIC ONCOLOGY, 2024, 181 : 186 - 186
  • [3] Tumor-reactive immunoglobulins in ovarian cancer: Diagnostic and therapeutic significance? (Review)
    Taylor, DD
    Gercel-Taylor, C
    ONCOLOGY REPORTS, 1998, 5 (06) : 1519 - 1524
  • [4] RETRACTED: Association between Immunohistochemistry Markers and Tumor Features and Their Diagnostic and Prognostic Values in Intrahepatic Cholangiocarcinoma (Retracted Article)
    He, Jiannan
    Zhang, Cao
    Shi, Qinye
    Bao, Fangping
    Pan, Xiang
    Kuai, Yue
    Wu, Jingjin
    Li, Li
    Chen, Ping
    Huang, Yian
    Xu, Jianhong
    COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2022, 2022
  • [5] RETRACTED: Diagnostic Value of Inflammatory Markers and Cytokines in Neonatal Sepsis (Retracted Article)
    Wu, Lijie
    Li, Jinku
    Ping, Lili
    Zhang, Xiaoli
    Zhai, Lina
    Li, Yanmin
    Zhang, Ruimin
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [6] RETRACTED: Comparison of tumor markers using different detection devices (Retracted Article)
    Tao, Rong
    Tu, Shaohua
    Liu, Chong
    Yang, Qi
    Zhu, Min
    Shen, Jiangfan
    ONCOTARGETS AND THERAPY, 2015, 8 : 1083 - 1090
  • [7] RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer (Retracted article. See vol. 175, pg. 192, 2023)
    Taylor, Douglas D.
    Gercel-Taylor, Cicek
    GYNECOLOGIC ONCOLOGY, 2008, 110 (01) : 13 - 21
  • [8] RETRACTED: Identification of Diagnostic Gene Markers and Immune Infiltration in Systemic Lupus (Retracted Article)
    Hu, Hongtao
    He, Chengsong
    COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2022, 2022
  • [9] RETRACTED: Changes of Tumor Markers in Patients with Lung Cancer after Immunotherapy and Their Link with Inflammation in the Body (Retracted Article)
    Liu, Li Wei
    Cai, Yuan Chun
    Tao, Xiao Lan
    Huang, Jing
    Han, Min
    COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2022, 2022
  • [10] RETRACTED: Resibufogenin suppresses tumor growth and inhibits glycolysis in ovarian cancer by modulating PIM1 (Retracted Article)
    Li, Qian
    Jiang, Chuanwu
    Wang, Yan
    Wei, Minghua
    Zheng, Huijin
    Xu, Yanqi
    Xu, Xuegang
    Jia, Fengyu
    Liu, Kai
    Sun, Gang
    Zang, Jianhua
    Mo, Ping
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2019, 392 (12) : 1477 - 1489